Bajaj Healthcare Becomes First in India to Receive SEC Recommendation for Cenobamate Tablets

Key Highlights Bajaj Healthcare has become the first company in India to receive a recommendation from the Subject Expert Committee (SEC) under the CDSCO for the manufacture and marketing of Cenobamate Tablets. Product Details • Cenobamate is an anti-seizure medication used for the treatment of partial-onset seizures in adults. • The SEC has recommended approval for six different strengths of the drug. Regulatory Update • The recommendation has been issued by the Subject Expert Committee (SEC). • Final marketing approval from the Central Drugs Standard Control Organisation (CDSCO) is still pending before commercial launch. What It Means • Being the first company to secure an SEC recommendation provides Bajaj Healthcare with a potential first-mover advantage in the Indian market. • The approval, once granted, could strengthen the company's neurology product portfolio. • It also reflects the company's growing capabilities in developing and commercializing specialty pharmaceutical products. Market Impact Impact: Positive The development is positive as it positions Bajaj Healthcare ahead of peers in bringing Cenobamate to the Indian market. However, commercial launch remains subject to final CDSCO approval. Learning Outcome In the pharmaceutical industry, an SEC recommendation is an important regulatory milestone, but commercialization can begin only after receiving final approval from the CDSCO. First-mover approvals can provide a competitive advantage and support future market share gains. $BAJAJHCARE